Indalpine

Summary

Indalpine (CHEMBL276520) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 228.33 Da · C15H20N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL276520
Name	Indalpine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	44668
Molecular formula	C15H20N2
Molecular weight	228.33
InChIKey	SADQVAVFGNTEOD-UHFFFAOYSA-N

SMILES: C1CNCCC1CCC2=CNC3=CC=CC=C32

IUPAC name: 3-(2-piperidin-4-ylethyl)-1H-indole

Also known as: Indalpina, Indalpine, LM-5008, INDALPINE

Parent form; salt/anhydrous children: CHEMBL2362557

Patent coverage: 893 distinct patent families (3,532 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 3,503 (99%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Sodium-dependent serotonin transporter, Sodium-dependent serotonin transporter, Sodium-dependent dopamine transporter.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 6 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P31652	8.7	Ki	2	nM	CHEMBL_ACT_1610202
P31652	8.7	Ki	2	nM	CHEMBL_ACT_566822
P31652	8.6	Ki	2.5	nM	CHEMBL_ACT_787057
P31652	8	IC50	10	nM	CHEMBL_ACT_418537
SLC6A4	7.52	IC50	30	nM	CHEMBL_ACT_418540

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).